ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
|
|
- Baldwin Tyler
- 7 years ago
- Views:
Transcription
1 [Version 8, 10/2012] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Seite 1 von 13
2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Suspension and solvent for suspension for injection for chickens 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance per dose: to PFU * live cell associated Marek`s Disease virus strain CVI 988 BP Host system: SPF chicken embryo fibroblasts *PFU = plaque forming units Excipients: For a full list of excipients, see section PHARMACEUTICAL FORM Suspension and solvent for suspension for injection. 4. CLINICAL PARTICULARS 4.1 Target species Chickens 4.2 Indications for use, specifying the target species For active immunisation of chickens against Marek`s disease to reduce mortality and lesions caused by the disease. Onset of immunity: 6 days Duration of immunity: 52 weeks 4.3 Contraindications None 4.4 Special warnings Maternally derived antibodies (MDA) may interfere with the development of an immune response. In case of a recent field infection or of the vaccination of the parent flock leading to a high level of MDA in the chickens, the timing and/or frequency of the vaccination schedule must be reconsidered. Vaccination of ornamental and exhibition fowl is not recommended. 4.5 Special precautions for use Special precautions for use in animals Only healthy chickens should be vaccinated. The vaccine strain spreads. Appropriate veterinary and husbandry measures should be taken to avoid spread of the vaccine strain to susceptible species. Special precautions to be taken by the person administering the veterinary medicinal product to animals Personal protective equipment consisting of goggles and gloves must be worn. Personnel involved in administering the veterinary medicinal product have to wash and disinfect hands after handling the vaccine. Seite 2 von 13
3 This product is stored in liquid nitrogen. The operator should be aware of the general precautions to be taken when thawing and opening the ampoules, especially concerning the protective equipment mentioned above. Liquid nitrogen causes serious freeze burns by getting contact with the skin. When opening the ampoules, hold them as far away from your body as possible in order to avoid injuries in case an ampoule explodes. If liquid nitrogen comes into contact with the skin, immediately warm the affected area by immersion in water at 29 ± 1 C or by use of body heat. Usually, there will be considerable pain during warming. Seek medical advice if full function and feeling are not rapidly restored. 4.6 Adverse reactions (frequency and seriousness) None known 4.7 Use during pregnancy, lactation or lay Do not use in birds in lay and breeding birds. 4.8 Interaction with other medicinal products and other forms of interaction Do not mix this vaccine with substances other than AviPro DILUJECT BLUE for which compatibility has been demonstrated. Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed with either AviPro SALMONELLA VAC E or AviPro SALMONELLA VAC T or AviPro SALMONELLA DUO or AviPro ND HB1 or AviPro IB H120. No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product, except those mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis. 4.9 Amounts to be administered and administration route may be administered by injection of 0.2 ml (1 dose) subcutaneously or intramuscularly after dilution of the virus suspension with the solvent AviPro DILUJECT BLUE. The chickens may be immunized from the 1st day of life but it is recommended to vaccinate as early as possible after hatch. Preparation: Immediately prior to vaccination one ampoule (2,000 doses) of the virus suspension is quickly thawed in a water bath at 27 C. Immediately after thawing, the ampoule is opened and the virus suspension (2,000 doses) diluted in 400 ml of solvent. The solvent should be at room temperature (20 C to 25 C). The vaccine suspension should be well mixed avoiding the buildup of foam also during administration (e.g. with a magnetic stirrer) in order to achieve a homogeneous suspension. Once diluted and reconstituted, the vaccine should be used immediately. Administration: Administer by a single injection subcutaneously in the neck or intramuscularly in the leg each bird as soon as possible after hatching to avoid infection with MD field viruses Overdose (symptoms, emergency procedures, antidotes), if necessary A tenfold dose has been demonstrated to be safe Withdrawal period(s) Zero days. 5. IMMUNOLOGICAL PROPERTIES Pharmacotherapeutic group: live virus vaccines for poultry, ATCvet code: QI01AD03 Seite 3 von 13
4 vaccine strain stimulates an active immune response against Marek s Disease in vaccinated chickens. 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients Antigen: medium traces, new-born calf serum and dimethyl sulfoxide. Solvent: disodium phosphate dehydrate, glucose monohydrate, potassium dihydrogen phosphate, dipotassium phosphate, sodium chloride, sucrose, enzymatic hydrolysate of casein and E131 patent blue V. 6.2 Incompatibilities Do not mix with any other veterinary medicinal product, except the solvent AviPro DILUJECT BLUE recommended for use with the product. 6.3 Shelf life Shelf-life of the veterinary medicinal product as packaged for sale (antigen): 24 months Shelf-life of the veterinary medicinal product as packaged for sale (solvent): 36 months Shelf-life after dilution or reconstitution according to directions: 2 hours 6.4. Special precautions for storage Vaccine: Store and transport frozen in liquid nitrogen at a temperature below -150 C. Solvent: Store below 25 C. Do not freeze Do not expose reconstituted vaccine to direct sunlight or heat. 6.5 Nature and composition of immediate packaging The vaccine is supplied in EP type I glass ampoules. The ampoules are heat sealed and contain 2000 doses of vaccine. The solvent is supplied in plastic bottles containing 400 ml. The bottles are closed with EP type I closure and sealed with aluminium caps. 6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities. 7. MARKETING AUTHORISATION HOLDER Lohmann Animal Health GmbH Heinz-Lohmann-Str Cuxhaven, Germany 8. MARKETING AUTHORISATION NUMBER(S) 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION <{DD/MM/YYYY}> <{DD month YYYY}> 10 DATE OF REVISION OF THE TEXT {MM/YYYY} or <month YYYY> PROHIBITION OF SALE, SUPPLY AND/OR USE Not applicable. Seite 4 von 13
5 ANNEX III LABELLING AND PACKAGE LEAFLET Seite 5 von 13
6 A. LABELLING Seite 6 von 13
7 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS {EP type I glass ampoules} 1. NAME OF THE VETERINARY MEDICINAL PRODUCT 2. QUANTITY OF THE ACTIVE SUBSTANCE(S) Suspension 3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 2000 doses 4. ROUTE(S) OF ADMINISTRATION IM / SC injection 5. WITHDRAWAL PERIOD 6. BATCH NUMBER Lot No.: 7. EXPIRY DATE EXP: 8. THE WORDS FOR ANIMAL TREATMENT ONLY Ad us vet Seite 7 von 13
8 PARTICULARS TO APPEAR ON THE OUTER PACKAGE PARTICULARS TO APPEAR ON IMMEDIATE PACKAGING UNITS {BOTTLE / BOX} 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AviPro DILUJECT BLUE, solvent for cell associated Lohmann vaccines 2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES List of substances: disodium phosphate dehydrate, glucose monohydrate, potassium dihydrogen phosphate, dipotassium phosphate, sodium chloride, sucrose, enzymatic hydrolysate of casein and E131 patent blue V. 3. PHARMACEUTICAL FORM Solution for manufacturing a suspension 4. PACKAGE SIZE 400 ml 5. TARGET SPECIES Target species: Chickens. 6. INDICATION(S) Not applicable 7. METHOD AND ROUTE(S) OF ADMINISTRATION Method and route of administration: Subcutaneous or intramuscular injection. 8. WITHDRAWAL PERIOD Withdrawal period: Zero days. 9. SPECIAL WARNING(S), IF NECESSARY Special warnings: Read the package leaflet before use. 10. EXPIRY DATE EXP 11. SPECIAL STORAGE CONDITIONS Storage conditions: Store below 25 C. Do not freeze. 12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY Not applicable 13. THE WORDS FOR ANIMAL TREATMENT ONLY AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable FOR ANIMAL TREATMENT ONLY. 14. THE WORDS KEEP OUT OF THE SIGHT AND REACH OF CHILDREN Keep out of the sight and reach of children. 15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Seite 8 von 13
9 Lohmann Animal Health GmbH Heinz-Lohmann-Str. 4, D Cuxhaven, Germany 16. MARKETING AUTHORISATION NUMBER(S) EU/0/00/000/ MANUFACTURER S BATCH NUMBER BATCH Seite 9 von 13
10 B. PACKAGE LEAFLET Seite 10 von 13
11 PACKAGE LEAFLET Suspension and solvent for suspension for injection for chickens 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Marketing authorisation holder, and manufacturer responsible for the batch release: Lohmann Animal Health GmbH Heinz-Lohmann-Str. 4, D Cuxhaven, Germany 2. NAME OF THE VETERINARY MEDICINAL PRODUCT Suspension and solvent for suspension for injection for chickens 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Active substance per dose: to PFU * live cell associated Marek`s Disease virus strain CVI 988 BP Host system: SPF chicken embryo fibroblasts *PFU = plaque forming units Excipients: Medium traces, new-born calf serum, dimethyl sulfoxide, disodium phosphate dehydrate, glucose monohydrate, potassium dihydrogen phosphate, dipotassium phosphate, sodium chloride, sucrose, enzymatic hydrolysate of casein and E131 patent blue V. 4. INDICATION(S) For active immunisation of chickens against Marek`s disease to reduce mortality and lesions caused by the disease. Onset of immunity: within 6 days Duration of immunity: 52 weeks. 5. CONTRAINDICATIONS None 6. ADVERSE REACTIONS None known If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon. 7. TARGET SPECIES Chickens 8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION Administer AviPro MD Maris from the first day of life by subcutaneous or intramuscular injection of 0.2 ml (1 dose) after dilution of the virus suspension with the solvent AviPro Diluject Blue. 9. ADVICE ON CORRECT ADMINISTRATION Preparation: Seite 11 von 13
12 Quickly thaw one ampoule (2,000 doses) of the virus suspension in a water bath at 27 C immediately prior to vaccination. Open the ampoule immediately after thawing, and dilute the virus suspension (2,000 doses) in 400 ml of solvent. The solvent should be at room temperature (20 C to 25 C). Mix the vaccine suspension well avoiding the build-up of foam also during administration (e.g. with a magnetic stirrer) in order to achieve a homogeneous suspension. Once diluted and reconstituted, the vaccine should be used immediately. Administration: Administer a single injection subcutaneously in the neck or intramuscularly in the leg each bird as soon as possible after hatching to avoid infection with MD field viruses. 10. WITHDRAWAL PERIOD Zero days 11. SPECIAL STORAGE PRECAUTIONS Keep out of the reach and sight of children. Vaccine: Storage and transport frozen in liquid nitrogen at a temperature below -150 C. Solvent: Storage below 25 C. Do not freeze Do not expose the vaccine suspension ready for use to direct sunlight or heat. Do not use after the expiry date stated on the label after EXP. Shelf-life after dilution or reconstitution according to directions: 2 hours 12. SPECIAL WARNING(S) Maternally derived antibodies (MDA) may interfere with the development of an immune response. In case of a recent field infection or of the vaccination of the parent flock leading to a high level of MDA in the chicks, the timing and/or frequency of the vaccination schedule must be reconsidered. Do not use in birds in lay and breeding birds. A tenfold dose has been demonstrated to be safe. Special precautions for use in animals Only healthy chickens should be vaccinated. The vaccine strain spreads. Appropriate veterinary and husbandry measures should be taken to avoid spread of the vaccine strain to susceptible species. Special precautions to be taken by the person administering the veterinary medicinal product to animals Always wear personal protective equipment consisting of goggles and gloves. Personnel involved in administering the veterinary medicinal product should wash and disinfect hands after handling the vaccine. This product is stored in liquid nitrogen. The operator should be aware of the general precautions to be taken when thawing and opening the ampoules, especially concerning the protective equipment mentioned above. Liquid nitrogen causes serious freeze burns by getting contact with the skin. When opening the ampoules, hold them as far away from your body as possible in order to avoid injuries in case an ampoule explodes. Seite 12 von 13
13 If liquid nitrogen comes into contact with the skin, immediately warm the affected area by immersion in water at 29 ± 1 C or by use of body heat. Usually, there will be considerable pain during warming. Seek medical advice if full function and feeling are not rapidly restored. Interactions Do not mix this vaccine with substances other than AviPro DILUJECT BLUE for which compatibility has been demonstrated. Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed either AviPro SALMONELLA VAC E or AviPro SALMONELLA VAC T or AviPro SALMONELLA DUO or AviPro ND HB1 or AviPro IB H120. No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product, except those mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis. 13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment. 14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED xxx 15. OTHER INFORMATION xxx Seite 13 von 13
Summary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT ACEGON, 50 microgram/ml, solution for injection for cattle. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ZULVAC 8 Ovis suspension for injection for sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 2 ml of
More informationSUMMARYOF PRODUCT CHARACTERISTICS
SUMMARYOF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Excis 10 mg/ml concentrate for solution for fish treatment 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Cypermethrin
More informationHaving regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof;
DIRECTIVE 65/65/EEC Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products (OJ L No 22 of
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution. Cyanocobalamin
PACKAGE LEAFLET: INFORMATION FOR THE USER VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution Cyanocobalamin Read all of this leaflet carefully before you start using this medicine because
More informationThe format of this leaflet was determined by the Ministry of Health and its content was checked and approved in May 2013.
The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in May 2013 Havrix 720 Junior 1 NAME OF THE MEDICINAL PRODUCT Havrix 720 Junior 2 QUALITATIVE
More informationPackage leaflet: Information for the patient. Naloxone Hydrochloride 20 micrograms / ml Solution for Injection Naloxone hydrochloride
A leaflet will be included in each pack. The leaflet will consist of a Technical Information Leaflet and a Patient Information Leaflet. The two leaflets will be easily separatable. The text of the Technical
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. PARACETAMOL MACOPHARMA 10 mg/ml, solution for infusion. Paracetamol
PACKAGE LEAFLET: INFORMATION FOR THE USER PARACETAMOL MACOPHARMA 10 mg/ml, solution for infusion Paracetamol Read all of this leaflet carefully before you start using this medicine. Keep this leaflet.
More informationRADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES
RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES Guideline Title Radiopharmaceuticals based on Monoclonal Antibodies Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC
More informationHypromellose Eye Drops BP 0.3% w/v PL 23097/0006
Hypromellose Eye Drops BP 0.3% w/v PL 23097/0006 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 9 Summary of product characteristics Page 10 Patient
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Aknemycin Solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 10 g of solution contains 0.2 g of erythromycin. Structural formula of
More informationMedicine Record Book
Medicine Record Book Medicine Administration and Purchase Record Book (and Beef/Lamb Stock Health Plan) Name:.. Address:........ Assurance Number:. CONTENTS Foreword Animal Health Plan (Beef& Lamb only)
More informationNEUROTONE THR 00904/0005 UKPAR
NEUROTONE THR 00904/0005 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Summary of Product Characteristics Page 11 Product Information Leaflet
More informationPerfalgan 10 mg/ml, solution for infusion
PACKAGE LEAFLET: INFORMATION FOR THE USER Perfalgan 10 mg/ml, solution for infusion Paracetamol Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need
More informationPackage Leaflet: Information for the user
Package Leaflet: Information for the user ZOSTAVAX Powder and solvent for suspension for injection in a pre-filled syringe shingles (herpes zoster) vaccine (live) Read all of this leaflet carefully before
More informationThe format of this leaflet was determined by the Ministry of Health and its content was checked and approved in September 2008 HAVRIX 1440
The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in September 2008 HAVRIX 1440 HAVRIX 720 Junior Monodose TITLE Hepatitis A (inactivated) vaccine
More informationSUMMARY OF PRODUCT CHARACTERISTICS
Registration No. : 2C 22/47 (N) Importer / Manufacturer: Sanofi Pasteur Ltd., Thailand/Sanofi Pasteur S.A., France SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICAL PRODUCT : PENTAXIM (Diphtheria,
More informationAQUATIC ANIMAL MEDICINE RECORD BOOK
AQUATIC ANIMAL MEDICINE RECORD BOOK FISH HEALTH INSPECTORATE www.efishbusiness.co.uk It is a legal requirement for you to retain these records for at least five years following the administration or other
More informationI B2.4. Design of the patient information leaflet for VariQuin
(English translation of official Dutch version) I B2.4. Design of the patient information leaflet for VariQuin Information for the Patient: Read this package leaflet carefully when you have some time to
More informationCollege ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board. Graadt van Roggenweg 500 3531 AH Utrecht The Netherlands
College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board Graadt van Roggenweg 500 3531 AH Utrecht The Netherlands DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HYPERICUM PERFORATUM L., HERBA (TRADITIONAL USE)
European Medicines Agency Evaluation of Medicines for Human Use London, 12 November 2009 Doc. Ref.: EMEA/HMPC/745582/2009 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH
More informationSODIUM CHLORIDE 0.9% W/V SOLUTION FOR INJECTION PL 01502/0068 UKPAR TABLE OF CONTENTS
SODIUM CHLORIDE 0.9% W/V SOLUTION FOR INJECTION PL 01502/0068 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Steps taken after authorisation
More informationMACROGOL COMPOUND ORAL POWDER (sodium chloride, sodium hydrogen carbonate, potassium chloride, macrogol 3350) PL 33579/0001 UKPAR TABLE OF CONTENTS
MACROGOL COMPOUND ORAL POWDER (sodium chloride, sodium hydrogen carbonate, potassium chloride, macrogol 3350) PL 33579/0001 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps
More informationNevirapine 200 mg tablets WHOPAR part 5 09/2010, version 1.0 (Matrix Laboratories Ltd), HA396 LABELLING. Page 1 of 8
LABELLING Page 1 of 8 PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING HDPE bottle carton label 1. NAME OF THE MEDICINAL PRODUCT Nevirapine
More informationCode of Practice on the responsible use of animal medicines on the farm
Code of Practice on the responsible use of animal medicines on the farm Updated: December 2014 Supported by the following organisations: Table of Contents Table of Contents... 2 Introduction... 3 Animal
More informationDonepezil hydrochloride 10 mg film-coated tablets PL 19156/0130
Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 12 Summary of Product Characteristics
More informationReport of the Veal Calf Vaccination Study with Rispoval IntraNasal (Zoetis)
Report of the Veal Calf Vaccination Study with Rispoval IntraNasal (Zoetis) Date: February 18, 2014 H. A. Vahl, H. Bekman and J. van Riel Introduction: Substantial percentages of antibiotics applied in
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 5 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationMUTUAL RECOGNITION PROCEDURE DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT
Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL) Federal Office of Consumer Protection and Food Safety Mauerstraße 39-42 10117 Berlin (Germany) MUTUAL RECOGNITION PROCEDURE DECENTRALISED
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Prednicare Tablets 5mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active Substance(s) Prednisolone
More informationHUMULIN 70/30 KwikPen
1 Instructions for Use HUMULIN 70/30 KwikPen (70% human insulin isophane suspension 30% human insulin injection [rdna origin]) Read the Instructions for Use before you start taking HUMULIN 70/30 and each
More informationOne vial contains 500 U* of C1-inhibitor** After reconstitution the product contains 500 U/5 ml which correspond to a concentration of 100 U/ml.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cetor 100 U/ml powder and solvent for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains 500 U* of
More informationImporter / Manufacturer: MSD (THAILAND) LTD./ Merck & Co.,Inc., West Point, Pennsylvania 19486 SUMMARY OF PRODUCT CHARACTERISTICS
Registration No. 1C 68/47(NC) Importer / Manufacturer: MSD (THAILAND) LTD./ Merck & Co.,Inc., West Point, Pennsylvania 19486 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICAL PRODUCT VARIVAX [Varicella
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Albuman 200 g/l is a solution containing 200 g/l (20%) of total protein of which at least 95% is human albumin.
Albuman 200 g/l SPC 01 December 2015 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Albuman 200 g/l solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Albuman 200 g/l
More informationAlways take this medicine exactly as described in this leaflet or as your doctor, pharmacist or nurse have told you.
leaflet: Information for the user Macrogol 4000 10 g powder for oral solution in sachet Macrogol 4000
More informationMucodyne-Clear 250 mg/5 ml Syrup PL 04425/0665
Mucodyne-Clear 250 mg/5 ml Syrup PL 04425/0665 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 9 Summary of product characteristics Page 10 Patient
More informationWard 29 guide to the safe preparation and administration of intravenous (IV) antibiotics at home
Ward 29 guide to the safe preparation and administration of intravenous (IV) antibiotics at home Contents Page Important contact numbers 1 General information on preparing and administering IV antibiotics
More informationPackage leaflet: Information for the patient. Laxido Orange, powder for oral solution
Package leaflet: Information for the patient Laxido Orange, powder for oral solution Read all of this leaflet carefully before you start taking this medicine because it contains important information for
More informationGeneral Legal Requirements A guide for pharmacists in Northern Ireland 2010 Edition. Medicines for Veterinary Use
General Legal Requirements A guide for pharmacists in Northern Ireland 2010 Edition 5 Medicines for Veterinary Use 5 MEDICINES FOR VETERINARY USE The Veterinary Medicines Regulations SI No. 2297 came into
More informationTdaP-Booster (tee-dee-ay-pee boo-ster)
New Zealand Consumer Medicine Information TdaP-Booster (tee-dee-ay-pee boo-ster) Tetanus, diphtheria and pertussis (acellular mono-component) vaccine (adsorbed, reduced antigen content) CONSUMER MEDICINE
More informationIMPORTANT: PLEASE READ
PART III: CONSUMER INFORMATION combined hepatitis A (inactivated) and hepatitis B (recombinant) vaccine This leaflet is part III of a three-part "Product Monograph" published when was approved for sale
More informationZOVIRAX Cold Sore Cream
Data Sheet ZOVIRAX Cold Sore Cream Aciclovir 5% w/w Presentation Topical cream Indications ZOVIRAX Cold Sore Cream is indicated for the treatment of Herpes simplex virus infections of the lips and face
More informationHow Does a Doctor Test for AIDS?
Edvo-Kit #S-70 How Does a Doctor Test for AIDS? S-70 Experiment Objective: The Human Immunodefi ciency Virus (HIV) is an infectious agent that causes Acquired Immunodefi ciency Syndrome (AIDS) in humans.
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Linezolid 2 mg/ml solution for infusion Linezolid 600mg film coated tablets Linezolid 100mg/5ml granules for oral suspension Procedure No: UK Licence No:
More informationAciclovir 200mg Tablets Aciclovir 400mg Tablets Aciclovir 800mg Tablets PL 29831/0517 PL 29831/0518 PL 29831/0519 UKPAR
Aciclovir 200mg Tablets Aciclovir 400mg Tablets Aciclovir 800mg Tablets PL 29831/0517 PL 29831/0518 PL 29831/0519 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la]
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr NUCALA [new-ka la] mepolizumab lyophilized powder for subcutaneous injection Read this carefully before you start
More informationUKPAR Goodnight THR 00904/0003. Goodnight THR 00904/0003 UKPAR TABLE OF CONTENTS. Lay Summary Page 2. Scientific discussion Page 3
Goodnight THR 00904/0003 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Steps taken after authorisation Page 13 Summary of Product Characteristics
More informationskin and soft tissue infections (skinfold pyoderma, impetigo, folliculitis, furunculosis, cellulitis) caused by susceptible strains of organisms.
Part II SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL P 5 mg tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active Ingredient Marbofloxacin 5mg per tablet
More informationFelimazole 5 mg Coated Tablet
.. CARTON TEXT - FRONT PANEL PRESCRIPTION ANIMAL REMEDY READ SAFETY DIRECTIONS BEFORE OPENING OR USING KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY RLP Approved Felimazole 5 mg Coated Tablet
More informationPromoting safer use of injectable medicines
Promoting safer use of injectable medicines A template standard operating procedure for: prescribing, preparing and administering injectable medicines in clinical areas Introduction The use of injectable
More informationOmeprazole 20 mg gastro-resistant tablets PL 14017/0277
Omeprazole 20 mg gastro-resistant tablets PL 14017/0277 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 11 Steps Taken After Initial Authorisation
More informationArnicare Arnica 30c pillules NR 01175/0181 UKPAR
Arnicare Arnica 30c pillules NR 01175/0181 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of product characteristics Page 12 Product
More informationGUIDANCE ON THE USE OF CASCADE
VETERINARY MEDICINES GUIDANCE NOTE No 13 GUIDANCE ON THE USE OF CASCADE Last updated July 2013 www.vmd.defra.gov.uk QUICK START GUIDE This Veterinary Medicines Guidance Note (VMGN) is aimed primarily at
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. STAMARIL, powder and solvent for suspension for injection in pre-filled syringe Yellow fever vaccine (Live)
PACKAGE LEAFLET: INFORMATION FOR THE USER STAMARIL, powder and solvent for suspension for injection in pre-filled syringe Yellow fever vaccine (Live) Read all of this leaflet carefully before you or your
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Buprenovet 0.3 mg/ml Solution for Injection for Dogs and Cats (AT, DE)
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Buprecare 0.3 mg/ml Solution for Injection for Dogs and Cats (UK, BE, FR, IE, LU, NL, ES) Buprenovet 0.3 mg/ml Solution for
More informationFor Educational Use Only - Not for Detailing or Distribution
This document is intended for healthcare professionals practicing in the United States and may contain information that has not been approved by the FDA. It is supplied to you as a professional courtesy
More informationPolio and the Introduction of IPV
Polio and the Introduction of IPV Poliomyelitis (polio) is a highly infectious disease that is caused when a person is infected by the polio virus that invades the nervous system. Poliomyelitis can cause
More informationISOPLEX 4% W/V SOLUTION FOR INFUSION (Succinylated gelatin) PL 13538/0017 UKPAR TABLE OF CONTENTS
ISOPLEX 4% W/V SOLUTION FOR INFUSION (Succinylated gelatin) PL 13538/0017 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Steps taken after authorisation
More informationThe clinical studies have been performed in children, adolescents and adults, from 4 years up to 55 years of age.
NAME OF THE MEDICINE TdaP-Booster. Diphtheria, tetanus and pertussis (acellular mono-component) vaccine (adsorbed, reduced antigen content). DESCRIPTION TdaP-Booster is a suspension for injection in pre-filled
More informationClikSTAR - Important facts about your new insulin delivery device.
ClikSTAR - Important facts about your new insulin delivery device. Instruction for Use ClikSTAR Insulin delivery device Before you start: Read these instructions and follow them completely each time you
More informationDechra Veterinary Products Limited (A business unit of Dechra Pharmaceuticals PLC) Sansaw Business Park Hadnall, Shrewsbury Shropshire SY4 4AS
Dechra Veterinary Products Limited (A business unit of Dechra Pharmaceuticals PLC) Sansaw Business Park Hadnall, Shrewsbury Shropshire SY4 4AS Tel: 01939 211200 Fax: 01939 211201 Email: info.uk@dechra.com
More informationPackage leaflet: Information for the patient. Entyvio 300 mg powder for concentrate for solution for infusion vedolizumab
Package leaflet: Information for the patient Entyvio 300 mg powder for concentrate for solution for infusion vedolizumab This medicine is subject to additional monitoring. This will allow quick identification
More informationHSE Guidelines for maintaining the vaccine cold-chain including maintenance of vaccine fridges and management of vaccines
HSE Guidelines for maintaining the vaccine cold-chain including maintenance of vaccine fridges and management of vaccines Document reference number Revision number Approval date NIO01 Document developed
More informationCollege ter Beoordeling van Geneesmiddelen (CBG) Medicines Evaluation Board (MEB) Graadt van Roggenweg 500 3531 AH Utrecht The Netherlands
MEB agency / Veterinary Medicinal Products Unit The Netherlands C B G M E B College ter Beoordeling van Geneesmiddelen (CBG) Medicines Evaluation Board (MEB) Graadt van Roggenweg 500 3531 AH Utrecht The
More informationGuidance Document Infectious Substances
Guidance Document Infectious Substances Note: 1. The following Guidance Document was developed by the ICAO DGP. The original ICAO document reflects references to the ICAO Technical Instructions these have
More informationIf you forget to use Catacrom Eye Drops If you forget to use this medicine, use it as soon as you remember.
Package leaflet: Information for the user Catacrom 2 % w/v Eye Drops, Solution Sodium cromoglicate Read all of this leaflet carefully before you start using this medicine because it contains important
More informationthe product for which protection was sought as "Centoxin (HA-lA Monoclonal Antibody";
COUNCIL REGULATION (EEC) No 1768/92 IN TiiE MATTER OF Application No SPC/GB93/172 for a Supplementary Protection Certificate in the name of Centocor, Inc DECISION Application No SPC/GB93/172 for a Supplementary
More informationAgencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio 8 28022 Madrid España (Reference Member State)
DEPARTAMENTO DE MEDICAMENTOS VETERINARIOS Medicamentos y Productos C/Campezo 1, Edificio 8 28022 Madrid España (Reference Member State) DECENTRALISED PROCEDURE [DRAFT] PUBLICLY AVAILABLE ASSESSMENT REPORT
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. ADRENALINE (TARTRATE) STEROP 1 mg/1 ml Solution for injection. Adrenaline (Levorenine, Epinephrine)
PACKAGE LEAFLET: INFORMATION FOR THE USER ADRENALINE (TARTRATE) STEROP 1 mg/1 ml Solution for injection Adrenaline (Levorenine, Epinephrine) Read all of this leaflet carefully before you start using this
More informationVersion: 2.2. 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING Product Identifier Material Name: Newcastle LaSota
Page 1 of 7 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING Product Identifier Trade Name: Synonyms: Chemical Family: Poulvac ND LaSota; Newcastle LaSota Poulvac ND LaSota; Newcastle
More informationInstructions for Use
1 Instructions for Use HUMULIN R U-500 KwikPen insulin human injection U-500 (500 units/ml, 3 ml pen) Important: Know your dose of HUMULIN R U-500 insulin. The Pen delivers your dose in insulin units.
More informationMENINGOCOCCAL GROUP B VACCINE (BEXSERO) Information for Health Professionals
MENINGOCOCCAL GROUP B VACCINE (BEXSERO) Information for Health Professionals What is Bexsero vaccine? Bexsero is a meningococcal Group B (MenB) vaccine which is indicated for the active immunisation of
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 5 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationDECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT
Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) Parque Empresarial Las Mercedes Edificio 8 C/ Campezo, 1 E - 28022 Madrid Spain (Reference Member State) DECENTRALISED PROCEDURE PUBLICLY
More informationMATERIAL SAFETY DATA SHEET
Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone
More informationVaccination Techniques
We know that a huge amount of effort, time and money goes into the research, development, manufacturing, regulation and distribution of vaccines. Such efforts are necessary to ensure vaccines are delivered
More informationMemantine hydrochloride 20 mg film-coated tablets PL 17907/0291
Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Steps Taken for Assessment Page 13 Summary of Product Characteristics
More informationMATERIAL SAFETY DATA SHEET (MSDS)/SAFETY DATA SHEET (SDS)
I. Product and Company Identification Product Name: VetScan FeLV-FIV Test A point of care blood diagnostic product Part Numbers: 250-0000-5, 250-0000-25 Manufactured For Abaxis By: SA Scientific, Inc.
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON AVENA SATIVA L., FRUCTUS
European Medicines Agency Evaluation of Medicines for Human Use London, 4 September 2008 Doc. Ref. EMEA/HMPC/368600/2007 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON
More informationN HUMAN Novo Nordisk Patient Information for Novolin N
N HUMAN Novo Nordisk Patient Information for Novolin N NOVOLIN N (NO-voe-lin) NPH, Human Insulin Isophane Suspension Injection (recombinant DNA origin) 100 units/ml Important: Know your insulin. Do not
More informationOverview of the Cattle Immune System 1
Oregon State University BEEF043 Beef Cattle Library Beef Cattle Sciences Overview of the Cattle Immune System 1 Reinaldo F. Cooke 2 Introduction On average, the U.S. cattle industry loses more than $1
More informationMINISTRY OF HEALTH PANDEMIC INFLUENZA A / H1N1 2009 VACCINE FREQUENTLY ASKED QUESTIONS
Government of the Republic of Trinidad and Tobago MINISTRY OF HEALTH PANDEMIC INFLUENZA A / H1N1 2009 VACCINE FREQUENTLY ASKED QUESTIONS Influenza vaccines are one of the most effective ways to protect
More informationNeedlestick Injury Prevention Assessment Tool
Needlestick Injury Prevention Assessment Tool WHO PROJECT TO PREVENT NEEDLESTICK INJURY and HIV TRANSMISSION AMONG HEALTHCARE WORKERS March 2005 Combined tool for assessing the safety of injections, suturing,
More informationHow To Use An Antibody
GUIDELINES FOR THE PRODUCTION OF ANTIBODIES IN LABORATORY ANIMALS Table of Contents 1. Purpose 2. Choice of Species and Strain 3. Immunizing Antigen 4. Procedures for Polyclonal Antibody Production 5.
More informationSummary of the risk management plan (RMP) for Ionsys (fentanyl)
EMA/764409/2015 Summary of the risk management plan (RMP) for Ionsys (fentanyl) This is a summary of the risk management plan (RMP) for Ionsys, which details the measures to be taken in order to ensure
More informationPATIENT INFORMATION LEAFLET. Calcium Sandoz Syrup calcium glubionate and calcium lactobionate
PATIENT INFORMATION LEAFLET Calcium Sandoz Syrup calcium glubionate and calcium lactobionate Read all of this leaflet carefully before you start taking this medicine Keep this leaflet. You may need to
More informationPackage leaflet : information for the user. Dilute Adrenaline/Epinephrine Injection 1:10,000 adrenaline (epinephrine) (as acid tartrate) 0.
Package leaflet : information for the user Dilute Adrenaline/Epinephrine Injection 1:10,000 adrenaline (epinephrine) (as acid tartrate) 0.1mg per ml Because of your condition it may not be possible for
More informationCODE OF PRACTICE TO MINIMIZE AND CONTAIN ANTIMICROBIAL RESISTANCE CAC/RCP 61-2005
CAC/RCP 61-2005 Page 1 of 15 CODE OF PRACTICE TO MINIMIZE AND CONTAIN ANTIMICROBIAL RESISTANCE CAC/RCP 61-2005 INTRODUCTION... 2 AIMS AND OBJECTIVES... 2 RESPONSIBILITIES OF THE REGULATORY AUTHORITIES...
More informationSummary of Product Characteristics
Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT FSME-IMMUN 0.25 ml Junior Suspension for injection in pre-filled syringe Tick-Borne Encephalitis Vaccine (Inactivated) 2. QUALITATIVE
More informationFootvax. First for footrot. The Sheep Farmer s Guide to: FOOTROT. and its control
The Sheep Farmer s Guide to: FOOTROT and its control Footvax First for footrot Contents Correct diagnosis of lameness... 4 Key facts about footrot... 5 What are the consequences of footrot?... 6 Why vaccinate
More informationROFERON-A PFS 3 M IU/0.5 ml
Safety Data Sheet ROFERON-A PFS 3 M IU/0.5 ml SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1. Product identifier Product name Product code ROFERON-A PFS 3 M IU/0.5
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Pharmaceuticals Brussels, SANCO/C8/AM/an D(2010) 380358 EudraLex The Rules Governing Medicinal Products in
More informationSomulose, 400 mg/25 mg/ml, Avlivningsvätska för djur Secobarbital Sodium. Applicant: Dechra Limited
NATIONAL PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT Somulose, 400 mg/25 mg/ml, Avlivningsvätska för djur Secobarbital Sodium Applicant: Dechra Limited Postadress/Postal
More informationSummary of Product Characteristics Medical Air
Summary of Product Characteristics Medical Air www.uk.airliquide.com 1. NAME OF THE MEDICINAL PRODUCT Medical Air 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Air Ph.Eur. 100% 3. PHARMACEUTICAL FORM Inhalation
More informationGuideline on stability testing for applications for variations to a marketing authorisation
21 March 2014 EMA/CHMP/CVMP/QWP/441071/2011- Rev.2 Committee for Medicinal Products for Human Use (CHMP)/ Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on stability testing for applications
More informationGuideline on dossier requirements for Type IA and IB notifications
Guideline on dossier requirements for Type IA and IB notifications In accordance with Regulation (EC) No 726/2004 and Directives 2001/83/EC and 2001/82/EC, a common approach to the procedures for variations
More informationPublic Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Olopatadine Zentiva 1 mg/ml eye drops, solution (olopatadine hydrochloride) Procedure No: UK Licence No: PL 17780/0568 Winthrop Pharmaceuticals UK Limited
More informationCommunity herbal monograph on Commiphora molmol Engler, gummi-resina
12 July 2011 EMA/HMPC/96911/2010 Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Commiphora molmol Engler, gummi-resina Final Discussion in Working Party on Community monographs
More informationHUMULIN (HU-mu-lin) N
Instructions for Use HUMULIN (HU-mu-lin) N (human insulin [rdna origin] isophane suspension) vial (100 Units/mL, U-100) Read the Instructions for Use before you start taking HUMULIN N and each time you
More informationFexofenadine Hydrochloride 120 mg Film-coated Tablets Fexofenadine Hydrochloride 180 mg Film-coated Tablets PL 36390/0053-4 UKPAR TABLE OF CONTENTS
Fexofenadine Hydrochloride 120 mg Film-coated Tablets Fexofenadine Hydrochloride 180 mg Film-coated Tablets PL 36390/0053-4 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 5 Steps
More information